Stacks
Interaction Unknown
No co-administration trial has tested BPC-157, TB-500, and MOTS-c together as of 2026. The grouping-versus-separation decision must be built from each compound's independent mechanism: BPC-157 on local tissue repair via FAK/VEGFR2, TB-500 on systemic actin dynamics and EPC recruitment, and MOTS-c on mitochondrial AMPK activation — three non-overlapping axes that make parallel grouping mechanistically defensible but empirically unvalidated.
August 4, 2026
·
9 min read
Stacks
Interaction Unknown
A 2025 retrospective clinical analysis found that postmenopausal women combining tirzepatide with menopausal hormone therapy (MHT) lost materially more body weight than those on tirzepatide alone. The mechanistic basis involves estrogen's direct modulation of GLP-1 receptor expression and adipose tissue lipolytic sensitivity — two pathways that converge with tirzepatide's dual GIP/GLP-1 receptor agonism to amplify the weight-loss signal.
August 3, 2026
·
9 min read
Stacks
Interaction Unknown
Among dual GLP-1/GIP receptor agonist protocols tracked in 2026, tirzepatide-anchored stacks with concurrent resistance training and ≥1.6 g/kg/day protein intake show the strongest lean mass preservation signal — approximately 74–75% of weight lost as fat mass versus 25–26% as lean mass (SURMOUNT-1 DEXA sub-study, Look et al. 2025). No co-administration RCT exists for any companion-compound pairing.
July 30, 2026
·
9 min read
Stacks
Interaction Unknown
The 2026 Abdul-Hafez et al narrative review (PMC12824524) establishes tirzepatide as a dual GIP/GLP-1 receptor co-agonist with five mechanistically distinct cardiovascular pathways. In the SUMMIT trial, it reduced the composite of cardiovascular death or worsening heart failure by 38% in obese HFpEF patients. Protocol designers must map each pathway to a separate interaction node.
July 29, 2026
·
10 min read
Stacks
Interaction Unknown
Yuan et al. (MDPI, 2026) characterise BPC-157 as operating across two separable axes — a regenerative axis anchored in VEGFR2–Akt–eNOS signalling and FAK/paxillin fibroblast activation, and an analgesic axis running through nitric oxide modulation and dopaminergic–opioid interaction. For stack designers, each axis creates a distinct interaction node: compounds converging on the same pathway require co-administration scrutiny.
July 21, 2026
·
9 min read
Stacks
Interaction Unknown
The 2026 Pharmaceuticals critical analysis (DOI: 10.3390/ph19020297) establishes that semaglutide produces tissue-specific GLP-1R outputs: cardioprotective in myocardium, proliferative in thyroid C-cells under rodent conditions. For cardio-oncology stack design, this dual signal means the compound can be a rational co-administration partner with anthracycline-class agents while requiring hard exclusion in thyroid-risk populations — two decisions made in parallel, not sequentially.
July 21, 2026
·
9 min read